Neuronyx's most advanced cell product development programs address spinal cord injury, brain tumor and Parkinson's disease. Neuronyx has developed a proprietary process for isolating and expanding these cells to provide extremely large, homogeneous cell populations with desirable therapeutic characteristics. This technology utilizes special cells that reside in adult bone marrow and that under certain conditions, have the ability to mature into a variety of specialized cells that may be used to treat a variety of conditions. Neuronyx is a development-stage biopharmaceutical company located in Malvern, Pennsylvania, focused on discovering, developing and delivering new medicines by applying unique technologies in adult stem cell biology. Neuronyx will receive an up-front payment and research support, is entitled to receive milestone payments upon certain regulatory events, and will manufacture the adult human bone marrow-derived cells for all phases of the collaboration. Under the agreement, Centocor and Neuronyx will conduct collaborative research, with Centocor taking responsibility for development and commercialization. "We believe these cells have the potential to improve cardiovascular outcomes following acute injury, such as myocardial infarction, as well as chronic indications, such as congestive heart failure, by facilitating the generation of new heart muscle or by replacing damaged cardiac tissue." "We are pleased that Centocor, a leading biopharmaceutical company with expertise and interest in the cardiovascular arena, will be working with our cells," said Hubert Schoemaker, Neuronyx's Chairman and Chief Executive Officer. announced that it has entered into an agreement with Centocor, Inc., a Johnson & Johnson company, for the development of cardiovascular therapies based on stem cells derived by Neuronyx from adult human bone marrow. MALVERN, Pa.-(BW HealthWire)-June 26, 2002-Neuronyx, Inc. He helped found Centocor in 1979, piloted the company through the collapse of its sepsis therapy (rejected by FDA for flaws in the statistical handling of its clinical trials) in 1992, served as chairman while the company recovered and became profitable, and left only when Johnson & Johnson bought Centocor in 1999.Īt that point, Schoemaker founded Neuronyx to use “adult bone marrow-derived stem cells to repair, regenerate and remodel tissue in acute and chronic disease settings.Neuronyx Announces Agreement with Centocor He downplayed his role in shaping the industry, and instead credited Centocor's employees, legislation that commercialized science, Wall Street investors, and America's entrepreneurial spirit.”įrom biotechnology’s earliest days, Schoemaker was, nonetheless, very visible as a spokesman for both Centocor and the industry. Schoemaker mentored many executives at area biotech firms, and helped elevate biotechnology into a growth industry in Southeastern Pennsylvania.
4 Philadelphia Inquirer ( ) noted, “As chairman of Centocor and cofounder of what later became the Eastern Technology Council, Dr.
He was 55 and had been diagnosed with medulloblastoma, the brain cancer that finally caused his death, in 1994.Īs his obituary in the Jan. Schoemaker, founder of Centocor (Horsham, PA, and Neuronyx (Malvern, PA, died on New Year’s Day at his home in Paoli, Pennsylvania.
0 kommentar(er)
